Name | R162 |
---|---|
Synonyms |
9,10-Anthracenedione, 1-hydroxy-2-(2-propen-1-yl)-
2-Allyl-1-hydroxy-9,10-anthraquinone |
Description | R162 is a potent inhibitor of glutamate dehydrogenase 1 (GDH1), with anti-cancer properties. |
---|---|
Related Catalog | |
In Vitro | Inhibition of GDH1 activity by R162 treatment results in decreased intracellular fumarate levels, attenuated GPx activity, increased ROS levels, and reduced cell proliferation in H1299 and MDA-MB231 cells, which can be significantly rescued by methyl-α-KG treatment as well as by antioxidant NAC. R162 inhibits cell proliferation and tumor growth potential of human cancer cells[1]. |
In Vivo | R162 (30 mg/kg/day, i.p.) does not result in a significant histopathological change between the vehicle-treated and R162-treated groups, nor alters complete blood counts, or hematopoietic properties in xenograft tumor mouse models. R162 (20 mg/kg/day) results in significantly decreased tumor growth and masses in mice compared with control mice and effectively inhibits GDH1 activity in resected tumors from xenograft nude mice[1]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 459.0±34.0 °C at 760 mmHg |
Molecular Formula | C17H12O3 |
Molecular Weight | 264.275 |
Flash Point | 245.5±22.2 °C |
Exact Mass | 264.078644 |
LogP | 4.99 |
Appearance | yellow solid |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Index of Refraction | 1.659 |
Storage condition | -20℃ |